Sphenopalatine neuralgia (SPN) is a rare craniofacial pain syndrome characterized by intense paroxysmal pain in the distribution of the sphenopalatine nerve. Despite its rarity, SPN presents a diagnostic and therapeutic challenge due to its overlapping clinical features with other facial pain syndromes. This review aims to elucidate the clinical features, diagnostic approaches, and management strategies for SPN based on the current literature and clinical experience.

Introduction: Sphenopalatine neuralgia (SPN) is a rare neuropathic pain disorder characterized by excruciating paroxysms of pain in the distribution of the sphenopalatine nerve. This condition presents diagnostic dilemmas due to its similarity to other trigeminal autonomic cephalalgias (TACs) such as cluster headache and trigeminal neuralgia. Understanding the distinct clinical features and appropriate diagnostic methods is crucial for accurate diagnosis and effective management of SPN.

Epidemiology: SPN is a rare condition, with limited epidemiological data available. It is more commonly reported in adults, with a slight male predominance. The exact prevalence remains uncertain due to underdiagnosis and misdiagnosis.

Clinical Features: SPN typically presents with unilateral, lancinating, or stabbing pain in the orbit, temple, forehead, and maxillary region, often radiating to the ipsilateral nose and cheek. The pain episodes are sudden in onset and can last from seconds to minutes, occurring multiple times a day. Patients may experience autonomic symptoms such as lacrimation, conjunctival injection, rhinorrhea, and nasal congestion during pain attacks, mimicking features of cluster headache. However, SPN is distinguished by the absence of restlessness or agitation commonly seen in cluster headache attacks.

Pathophysiology: The exact pathophysiology of SPN remains incompletely understood. Proposed mechanisms include compression, irritation, or injury to the sphenopalatine ganglion or its branches, leading to aberrant firing of nociceptive neurons. Additionally, vascular compression or inflammation may contribute to nerve dysfunction.

Diagnosis: The diagnosis of SPN relies on clinical history and examination. Neuroimaging studies such as magnetic resonance imaging (MRI) may be indicated to rule out structural lesions or vascular abnormalities. Diagnostic nerve blocks targeting the sphenopalatine ganglion can provide both diagnostic confirmation and therapeutic relief.

Management: Management of SPN involves a multimodal approach aimed at reducing pain frequency and intensity. Pharmacological interventions include the use of tricyclic antidepressants, anticonvulsants, and nerve membrane stabilizers such as gabapentin and pregabalin. In refractory cases, invasive procedures such as sphenopalatine ganglion blocks, radiofrequency ablation, or surgical interventions may be considered. Non-pharmacological modalities including acupuncture, physical therapy, and cognitive-behavioral therapy can complement pharmacotherapy in comprehensive pain management.

Conclusion: Sphenopalatine neuralgia is a rare but debilitating craniofacial pain syndrome that poses diagnostic and therapeutic challenges to healthcare providers. Accurate diagnosis relies on recognizing its distinct clinical features and performing appropriate diagnostic evaluations. A multimodal treatment approach addressing both pharmacological and non-pharmacological interventions is essential for improving patient outcomes and quality of life. Further research is needed to elucidate the underlying pathophysiology and optimize therapeutic strategies for SPN.